Literature DB >> 10073583

Survivorship analysis of hips treated with core decompression for nontraumatic osteonecrosis of the femoral head.

K J Bozic1, D Zurakowski, T S Thornhill.   

Abstract

We reviewed the long-term results of core decompression for the treatment of nontraumatic osteonecrosis of the femoral head, performed in thirty-four patients (fifty-four hips) between January 1, 1981, and June 30, 1995. Twenty patients (59 percent) had bilateral involvement. The mean age of the patients at the time of presentation was thirty-eight years (range, twenty-two to eighty-three years). The presumed risk factors were use of corticosteroids (thirty-seven hips), excessive intake of alcohol (eight hips), and use of adrenocorticotropic hormone for the treatment of multiple sclerosis (two hips); the remaining seven hips had idiopathic osteonecrosis. According to a modification of the classification system of Ficat and Arlet in combination with the system of Steinberg et al., thirteen hips were stage I (normal radiographs) preoperatively; seven, stage IIA sclerotic; sixteen, stage IIA cystic or sclerocystic; ten, stage IIB (transitional stage, with a crescent sign); and eight, stage III (collapse). The mean duration of follow-up after the core decompression was 120 months (range, twenty-four to 196 months). The result was considered successful if the patient was asymptomatic, with no progression of the disease, and unsuccessful if there was radiographic failure (progression to stage III [collapse]) or clinical failure (the need for a subsequent operation), or both. The Kaplan-Meier product-limit method was used to estimate clinical and radiographic survival. Overall, twenty-six hips (48 percent) had a satisfactory clinical result and twenty (37 percent) survived according to radiographic criteria. Radiographic or clinical failure, or both, were seen in four of the thirteen stage-I hips, none of the seven stage-IIA sclerotic hips, thirteen of the sixteen stage-IIA cystic or sclerocystic hips, nine of the ten stage-IIB hips, and all eight stage-III hips. On the basis of the Cox proportional-hazards regression model, significant predictors of overall failure included an advanced preoperative radiographic stage (p < 0.0001), a shorter duration of symptoms (p < 0.05), and use of corticosteroids (p < 0.05). No association was found between age, gender, excessive intake of alcohol, or renal transplantation and the overall outcome. Two patients (two hips; 4 percent) had a postoperative complication. One patient had a fracture of the femoral neck, and the other had a hematoma. Our findings suggest that core decompression is a safe and effective procedure for the treatment of stage-I or stage-IIA sclerotic disease. These data also demonstrate the importance of differentiating between stage-IIA sclerotic disease and stage-IIA cystic or sclerocystic disease. We believe that core decompression has a limited role in the operative management of patients who have evidence of cystic changes in the femoral head on plain radiographs.

Entities:  

Mesh:

Year:  1999        PMID: 10073583     DOI: 10.2106/00004623-199902000-00007

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  49 in total

1.  Open reduction and cementation for femoral head fracture secondary to avascular necrosis: preliminary report.

Authors:  M L Wood; C M McDowell; T L Kerstetter; S S Kelley
Journal:  Iowa Orthop J       Date:  2000

2.  CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.

Authors:  Cody C Wyles; Christopher R Paradise; Matthew T Houdek; Susan L Slager; Andre Terzic; Atta Behfar; Andre J van Wijnen; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

3.  Untreated asymptomatic hips in patients with osteonecrosis of the femoral head.

Authors:  Byung-Woo Min; Kwang-Soon Song; Chul-Hyun Cho; Sung-Moon Lee; Kyung-Jae Lee
Journal:  Clin Orthop Relat Res       Date:  2008-03-08       Impact factor: 4.176

4.  Investigating clinical failure of core decompression with autologous bone marrow mononuclear cells grafting for the treatment of non-traumatic osteonecrosis of the femoral head.

Authors:  Lihua Liu; Fuqiang Gao; Wei Sun; Yunting Wang; Qingyu Zhang; Bailiang Wang; Liming Cheng; Zi-Rong Li
Journal:  Int Orthop       Date:  2018-04-13       Impact factor: 3.075

5.  Will a vascularized greater trochanter graft preserve the necrotic femoral head?

Authors:  Dewei Zhao; Benjie Wang; Lin Guo; Lei Yang; Fengde Tian
Journal:  Clin Orthop Relat Res       Date:  2009-11-07       Impact factor: 4.176

6.  Osseoscopy: Direct Visualization to Assist Core Decompression and Debridement of Necrotic Bone Defects.

Authors:  William C Geisert; Aaron M Perdue; Kagan Ozer
Journal:  Arthrosc Tech       Date:  2017-05-15

7.  A modified porous tantalum implant technique for osteonecrosis of the femoral head: survivorship analysis and prognostic factors for radiographic progression and conversion to total hip arthroplasty.

Authors:  Yaosheng Liu; Xiuyun Su; Shiguo Zhou; Lei Wang; Cheng Wang; Shubin Liu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

8.  A current review of core decompression in the treatment of osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Julio J Jauregui; Randa K Elmallah; Carlos J Lavernia; Michael A Mont; James Nace
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

9.  Long-term results of decompression and muscle-pedicle bone grafting for osteonecrosis of the femoral head.

Authors:  Durgapada P Baksi; Ananda Kisor Pal; Debadyuti D Baksi
Journal:  Int Orthop       Date:  2007-11-09       Impact factor: 3.075

10.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.